|
|
Additional
Resources
|
|
Arthritis Q&A: Understanding Different Types Of Arthritis
By Alex Trenor
* What exactly is arthritis?Arthritis is a group of conditions that affect the health of the bone joints in the body. A painful inflammation of a joint or joints usually produces heat and Read more...
|
|
|
|
Arthritis
Major Medical Breakthrough: Arthritis Pill Without Side Effects Available At 25again.com
Minneapolis, MN June 7, 2005 -- In a world without Vioxx and Celebrex, 40 million Americans who suffer pain now have a safe alternative. In a major research breakthrough, 25AGAIN (www.25again.com), a nonprescription natural daily supplement, relieves pain safely with no side effects, backed by a 100% money-back guarantee.Proven by extensive clinical research, including a landmark Stanford University study on lupus patients, the active ingredient in 25AGAIN has significant anti-inflammatory action that relieves joint pain quickly and effectively.25AGAIN's active natural ingredient is DHEA, derived from the Mexican wild yam. DHEA, often called the anti-aging hormone, is the most plentiful circulating hormone in the body. Produced daily by the adrenal glands, DHEA levels decline dramatically after age 25, causing the onset of aging -- including arthritis, which generally occurs after age 40, when the body makes only half the
normal level of DHEA.25AGAIN naturally supplements the body's own production of DHEA back to normal youthful levels, relieving pain by reducing the inflammation of the synovial membranes, the tissues that line the joints."25AGAIN worked so well, I bought the company," states Wayne Josephson, 55, president. "As an aging baby boomer, I began to get in my hands. None of the over-the-counter pain pills worked. Within days of taking 25AGAIN, the pain and stiffness disappeared and has not returned."About 25AGAIN.com:25AGAIN.com is the exclusive internet marketer of the 25AGAIN Anti-Aging Pill, a nonprescription natural daily supplement. Its active ingredient DHEA has been proven safe and effective by over 2,000 clinical studies -- including Harvard, Stanford, the American Medical Association, and New York Academy of Sciences (see the Research page at www.25again.com). 25AGAIN relieves arthritis, osteoporosis, anxiety, depression and PMS, and improves energy, fat loss, lean muscle, bone density and skin moisture.Contact:Wayne Josephson, President952-465-4922http://www.25again.com.
We strive to provide only quality information, so
if
there is a specific topic related to arthritis
that you would
like us to cover, please contact us at any time.
And again, thank you to those contributing daily to
our Arthritis
Website, especially
regarding "relieving arthritis pain".
Discounted
Arthritis Online Auction
If you can't find the
Arthritis information you are looking for please
try our Google
Search
Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid Arthritis
<b>Condition</b>: Rheumatoid Arthritis<br/><b>Intervention</b>: Biological: adalimumab (Humira)<br/><b>Sponsor</b>: Abbott<br/><b>Active, not recruiting</b> - verified February 2010
A Study on the Prevalence of the Anti-MCV Anti-body in an Irish Rheumatoid Arthritis (RA) Population and the Impact of Biomarker Status on the Management of Irish Patients With Early RA
<b>Condition</b>: Rheumatoid Arthritis<br/><b>Intervention</b>: Other: This is a non-drug study. No treatment is mandated by the protocol. Routine blood draws (as per normal clinical care) will be taken through the study.<br/><b>Sponsors</b>: Abbott; Clinical Trial End-Point (CTEP) Ltd; JSS Medical Research Inc.<br/><b>Not yet recruiting</b> - verified March 2010
Cost Utility Analyses of Adalimumab Treatment in Patients With Rheumatoid Arthritis (RA)
<b>Condition</b>: Rheumatoid Arthritis<br/><b>Intervention</b>: <br/><b>Sponsors</b>: Abbott; Institute of Political Economical & Social Researches, Greece<br/><b>Active, not recruiting</b> - verified February 2010
Effectiveness of Adalimumab on Extraarticular Manifestation in Patients With Active Rheumatoid Arthritis
<b>Conditions</b>: Active Rheumatoid Arthritis; Osteoporoses<br/><b>Intervention</b>: <br/><b>Sponsors</b>: Abbott; Centre of Biostatistics and Analyses, Faculty of Medicine, Masaryk University Brno, Czech Republic<br/><b>Recruiting</b> - verified February 2010
The Relation Between Dedicated Extremity MRI Synovitis and Structural Deterioration Radiographic in Patients With Rheumatoid Arthritis in Clinical Remission. Preliminary Study
<b>Condition</b>: Rheumatoid Arthritis<br/><b>Intervention</b>: Other: MRI<br/><b>Sponsor</b>: Centre Hospitalier Universitaire de Nice<br/><b>Not yet recruiting</b> - verified January 2010
Efficacy of Oncoxin Plus Viusid in the Treatment of Rheumatoid Arthritis
<b>Condition</b>: Rheumatoid Arthritis<br/><b>Interventions</b>: Dietary Supplement: Oncoxin + Viusid; Dietary Supplement: Placebo<br/><b>Sponsor</b>: Catalysis SL<br/><b>Recruiting</b> - verified November 2009
Monitoring Epstein-Barr Virus (EBV) Load in Rheumatoid Arthritis Patients Treated With New Immunosuppressive Drugs
<b>Condition</b>: Rheumatoid Arthritis<br/><b>Intervention</b>: Biological: Venous blood sample<br/><b>Sponsor</b>: Assistance Publique Hopitaux De Marseille<br/><b>Recruiting</b> - verified October 2009
A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis
<b>Condition</b>: Rheumatoid Arthritis<br/><b>Interventions</b>: Drug: PF-04171327 10 mg; Other: Prednisone Placebo; Drug: PF-04171327 25 mg; Other: Prednisone Placebo; Drug: Prednisone 5 mg; Other: Placebo for PF-04171327; Other: Placebo; Other: Placebo for PF-04171327<br/><b>Sponsor</b>: Pfizer<br/><b>Recruiting</b> - verified March 2010
Targeting Synovitis in Early Rheumatoid Arthritis
<b>Conditions</b>: Rheumatoid Arthritis; Polyarthritis<br/><b>Interventions</b>: Other: Musculoskeletal Ultrasound; Other: 28 Joint Disease Activity Score<br/><b>Sponsors</b>: NHS Greater Glasgow and Clyde; University of Glasgow; Chief Scientist Office of the Scottish Government; Wyeth; Translational Medicine Research Collaboration<br/><b>Recruiting</b> - verified September 2009
Living Well With Rheumatoid Arthritis
<b>Condition</b>: Rheumatoid Arthritis<br/><b>Interventions</b>: Behavioral: Self-Help Group; Other: Education (Control) Group<br/><b>Sponsors</b>: Brigham and Women's Hospital; Bristol-Myers Squibb<br/><b>Recruiting</b> - verified September 2009
A Study to Evaluate the RNA Signature of Rheumatoid Arthritis From Synovium and Whole Blood
<b>Condition</b>: Rheumatoid Arthritis<br/><b>Intervention</b>: <br/><b>Sponsors</b>: Imperial College London; Merck<br/><b>Recruiting</b> - verified February 2010
Ultrasonography as a Biomarker in Early Rheumatoid Arthritis
<b>Condition</b>: Rheumatoid Arthritis<br/><b>Intervention</b>: <br/><b>Sponsors</b>: Imperial College London; Medical Research Council<br/><b>Recruiting</b> - verified February 2010
Evaluation of EULAR-RAID Score in Rheumatoid Arthritis Patients
<b>Condition</b>: Active Rheumatoid Arthritis<br/><b>Intervention</b>: Drug: Etanercept<br/><b>Sponsor</b>: Wyeth<br/><b>Recruiting</b> - verified July 2009
A Study Comparing CRx-102 Plus Disease-Modifying Anti-Rheumatic Drug (DMARD) Therapy to Placebo Plus DMARD Therapy in Rheumatoid Arthritis
<b>Condition</b>: Rheumatoid Arthritis<br/><b>Interventions</b>: Other: CRx-102 plus DMARD therapy; Other: Placebo plus DMARD therapy<br/><b>Sponsor</b>: CombinatoRx<br/><b>Completed</b> - verified September 2008
Effects of Tranilast on Pharmacokinetics of Methotrexate (MTX) in Patients With Rheumatoid Arthritis (RA)
<b>Condition</b>: Rheumatoid Arthritis<br/><b>Interventions</b>: Drug: Tranilast; Drug: Placebo comparator<br/><b>Sponsors</b>: Imperial College London; Nuon Therapeutics, Inc.<br/><b>Withdrawn</b> - verified July 2009
RESTART C0168Z05 Rheumatoid Arthritis Study
<b>Condition</b>: Rheumatoid Arthritis<br/><b>Intervention</b>: Biological: Infliximab<br/><b>Sponsors</b>: Centocor Ortho Biotech Services, L.L.C.; Schering-Plough<br/><b>Active, not recruiting</b> - verified January 2010
Humira in Rheumatoid Arthritis - Do Bone Erosions Heal?
<b>Conditions</b>: Rheumatoid Arthritis; Arthritis; Joint Diseases<br/><b>Intervention</b>: Drug: Adalimumab (Humira)<br/><b>Sponsors</b>: Hvidovre University Hospital; Abbott<br/><b>Completed</b> - verified June 2008
Rosuvastatin in Rheumatoid Arthritis (RORA)
<b>Condition</b>: Rheumatoid Arthritis<br/><b>Interventions</b>: Drug: rosuvastatin; Drug: placebo<br/><b>Sponsor</b>: University of Dundee<br/><b>Completed</b> - verified May 2008
Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study
<b>Condition</b>: Rheumatoid Arthritis<br/><b>Interventions</b>: Drug: Certolizumab pegol; Other: Placebo<br/><b>Sponsor</b>: UCB, Inc.<br/><b>Recruiting</b> - verified February 2010
Study Evaluating Single Doses of SBI-087 in Subjects With Rheumatoid Arthritis
<b>Condition</b>: Rheumatoid Arthritis<br/><b>Intervention</b>: Drug: SBI-087<br/><b>Sponsors</b>: Wyeth; Trubion Pharmaceuticals<br/><b>Active, not recruiting</b> - verified July 2009
|
|
